Related references
Note: Only part of the references are listed.Effect of papaverine on developmental hyperserotonemia induced autism spectrum disorder related behavioural phenotypes by altering markers of neuronal function, inflammation, and oxidative stress in rats
Kanishk Luhach et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2021)
Attenuation of neurobehavioural abnormalities by papaverine in prenatal valproic acid rat model of ASD
Kanishk Luhach et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders
Sebastien Delhaye et al.
MOLECULAR PSYCHIATRY (2021)
Vinpocetine amended prenatal valproic acid induced features of ASD possibly by altering markers of neuronal function, inflammation, and oxidative stress
Kanishk Luhach et al.
AUTISM RESEARCH (2021)
Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder
Mahmoud S. Abdallah et al.
CNS NEUROSCIENCE & THERAPEUTICS (2021)
Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder
Kanishk Luhach et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2021)
Mitochondrial dysfunction: A hidden trigger of autism?
Vellingiri Balachandar et al.
GENES & DISEASES (2021)
Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial
Fatemeh Hendouei et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial?
Arghavan Ayatollahi et al.
CLINICAL NEUROPHARMACOLOGY (2020)
Adenylate cyclase activator forskolin alleviates intracerebroventricular propionic acid-induced mitochondrial dysfunction of autistic rats
Sidharth Mehan et al.
NEURAL REGENERATION RESEARCH (2020)
Pharmacological Potential of Cilostazol for Alzheimer's Disease
Kenjiro Ono et al.
FRONTIERS IN PHARMACOLOGY (2019)
Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014
Jon Baio et al.
MMWR SURVEILLANCE SUMMARIES (2018)
Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study
Farzin Rezaei et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2017)
Isoform-specific subcellular localization and function of protein kinase A identified by mosaic imaging of mouse brain
Ronit Ilouz et al.
ELIFE (2017)
Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study
Shu-Yu Tai et al.
BMC NEUROLOGY (2017)
PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine
Wenda Xue et al.
SCIENTIFIC REPORTS (2016)
N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety
Mohammadali Nikoo et al.
CLINICAL NEUROPHARMACOLOGY (2015)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Brain Region-Specific Decrease in the Activity and Expression of Protein Kinase A in the Frontal Cortex of Regressive Autism
Lina Ji et al.
PLOS ONE (2011)
Cyclic AMP - Master regulator of innate immune cell function
Carlos H. Serezani et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
The cyclic AMP phenotype of fragile X and autism
Daniel J. Kelley et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2008)
Applied behavior analysis treatment of autism: The state of the art
Richard M. Foxx
CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA (2008)
Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
Shinya Goto
ATHEROSCLEROSIS SUPPLEMENTS (2005)